|Bid||0.6550 x 0|
|Ask||0.6750 x 0|
|Day's range||0.6600 - 0.6600|
|52-week range||0.6400 - 17.0000|
|Beta (5Y monthly)||1.54|
|PE ratio (TTM)||N/A|
|Earnings date||14 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||28.10|
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. The discussion will take place on Wednesday, November 30, 2022 at 1:00 p.m. ET (10:00 a.m. PT). A live audio webcast of the fireside chat will be available in the Investors section of the Harpoon T
Celebrations may be in order for Harpoon Therapeutics, Inc. ( NASDAQ:HARP ) shareholders, with the analysts delivering...
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 41.67% and 73.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?